Could a cancer drug boost radiation for rare sarcomas?
NCT ID NCT02787642
First seen Feb 26, 2026 · Last updated Jun 22, 2026 · Updated 20 times
Summary
This early-phase trial tested whether adding the drug olaparib to standard radiation therapy is safe for people with advanced soft-tissue sarcoma that cannot be removed by surgery. 41 participants received olaparib pills alongside daily radiation for about 7.5 weeks. The main goals were to find the highest safe dose and to check for serious side effects. This study does not yet prove the combination works better than radiation alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre Léon Bérard
Lyon, 69373, France
-
Institut Bergonié
Bordeaux, 33076, France
-
Institut Claudius Regaud - IUCT
Toulouse, 31052, France
-
Institut du Cancer de Montpellier
Montpellier, 34298, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Olaparib (a drug that may make cancer cells more sensitive to radiation)
What this could lead to
If successful, this could point toward a new way to treat advanced soft-tissue sarcoma by combining a targeted drug with standard radiation.
What could go wrong
This is an early Phase 1 trial with only 41 participants, focused on safety and dosing. It is not yet known if the combination works better than radiation alone, and there may be serious side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.